Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cantargia AB ( (SE:CANTA) ) just unveiled an update.
Cantargia AB will publish its interim report for the first quarter of 2026 on May 19 and will host an English-language audiocast and teleconference the same day, where CEO Hilde Steineger and CFO Patrik Renblad will present the results and take questions from investors, analysts, and media. The event, which will be accessible live and on demand via the company’s website, underscores Cantargia’s efforts to maintain transparent communication with the market as it advances its antibody-based therapies and navigates its post-CAN10 divestment strategy.
The most recent analyst rating on (SE:CANTA) stock is a Buy with a SEK14.00 price target. To see the full list of analyst forecasts on Cantargia AB stock, see the SE:CANTA Stock Forecast page.
More about Cantargia AB
Cantargia AB is a Swedish biotechnology company developing antibody-based treatments for life-threatening diseases, built on a platform targeting the protein IL1RAP, which is implicated in various cancers and inflammatory conditions. Its lead oncology antibody, nadunolimab (CAN04), is in clinical trials mainly in combination with chemotherapy for pancreatic cancer and non-small cell lung cancer, while its second program, CAN10, targeting autoimmune and inflammatory diseases, was acquired by Otsuka Pharmaceutical in 2025.
Average Trading Volume: 1,752,784
Technical Sentiment Signal: Sell
Current Market Cap: SEK896M
For a thorough assessment of CANTA stock, go to TipRanks’ Stock Analysis page.